Warning letter
Mary Greeley Medical Center: warning letter of Sep 21, 2004
FDA warning letter UCM146607 · Kansas City District Office
Key facts
| Reference number | UCM146607 |
|---|---|
| Company | Mary Greeley Medical Center |
| Subject | GMP for Blood & Blood Components/Adulterated |
| Issue date | Sep 21, 2004 |
| Posted date | Sep 21, 2004 |
| Issuing office | Kansas City District Office |
| Product type | Biologics |
| CFR sections cited | 601.12(b), 606.170(b), 610.40(h), 211.25(a), 211.100(b), 606.171, 606.160(a)(1), 606.160(b)(2)(ii), 606.160(b)(3)(i), 606.160(b) |
| Country | 3 |
| Inspection city | Ames |
| Inspection ZIP | 50010-5745 |
| Inspection start date | Apr 27, 2004 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: